These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 12946055)

  • 21. Alternatives to levodopa in the initial treatment of early Parkinson's disease.
    Lees A
    Drugs Aging; 2005; 22(9):731-40. PubMed ID: 16156677
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Community and long-term care management of Parkinson's disease in the elderly: focus on monoamine oxidase type B inhibitors.
    Chen JJ; Fernandez HH
    Drugs Aging; 2007; 24(8):663-80. PubMed ID: 17702535
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Designing prodrugs for the treatment of Parkinson's disease.
    Sozio P; Cerasa LS; Abbadessa A; Di Stefano A
    Expert Opin Drug Discov; 2012 May; 7(5):385-406. PubMed ID: 22494466
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dopamine heteroreceptor complexes as therapeutic targets in Parkinson's disease.
    Fuxe K; Guidolin D; Agnati LF; Borroto-Escuela DO
    Expert Opin Ther Targets; 2015 Mar; 19(3):377-98. PubMed ID: 25486101
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plausible improvements for selective targeting of dopamine receptors in therapy of Parkinson's disease.
    Luthra PM; Kumar JB
    Mini Rev Med Chem; 2012 Dec; 12(14):1556-64. PubMed ID: 22697513
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of dopamine receptor agonists in the treatment of early Parkinson's disease.
    Bonuccelli U; Del Dotto P; Rascol O
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S44-53. PubMed ID: 20123557
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Real-Life Search for the Optimal Set of Conversion Factors to Levodopa-Equivalent-Dose in Parkinson's Disease Patients on Polytherapy.
    Snineh MA; Hajyahya A; Linetsky E; Eitan R; Bergman H; Israel Z; Arkadir D
    J Parkinsons Dis; 2020; 10(1):173-178. PubMed ID: 31868682
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of dopamine agonists in early Parkinson's disease.
    Watts RL
    Neurology; 1997 Jul; 49(1 Suppl 1):S34-48. PubMed ID: 9222273
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Chase TN
    Drugs; 1998; 55 Suppl 1():1-9. PubMed ID: 9483164
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease.
    Fariello RG
    Drugs; 1998; 55 Suppl 1():10-6. PubMed ID: 9483165
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pramipexole--a new dopamine agonist for the treatment of Parkinson's disease.
    Bennett JP; Piercey MF
    J Neurol Sci; 1999 Feb; 163(1):25-31. PubMed ID: 10223406
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.
    Fernandez HH; Chen JJ
    Pharmacotherapy; 2007 Dec; 27(12 Pt 2):174S-185S. PubMed ID: 18041937
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selegiline: a molecule with innovative potential.
    Tábi T; Vécsei L; Youdim MB; Riederer P; Szökő É
    J Neural Transm (Vienna); 2020 May; 127(5):831-842. PubMed ID: 31562557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of early Parkinson's disease.
    Hauser RA; Zesiewicz TA
    Med Clin North Am; 1999 Mar; 83(2):393-414, vi. PubMed ID: 10093585
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent advances in Parkinson's disease.
    Vécsei L
    Ideggyogy Sz; 2002 Nov; 55(11-12):406-7. PubMed ID: 12632802
    [No Abstract]   [Full Text] [Related]  

  • 36. Dopaminergic agonists in the treatment of Parkinson's disease: a review.
    Piccoli F; Riuggeri RM
    J Neural Transm Suppl; 1995; 45():187-95. PubMed ID: 8748625
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of dopamine agonists in the treatment of early Parkinson's disease.
    Olanow CW
    Neurology; 2002 Feb; 58(4 Suppl 1):S33-41. PubMed ID: 11909983
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy?
    Mercuri NB; Bernardi G
    Trends Pharmacol Sci; 2005 Jul; 26(7):341-4. PubMed ID: 15936832
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Dopamine agonists--pharmacological similarities and differences].
    Honczarenko K; Białecka M
    Neurol Neurochir Pol; 2007; 41(2 Suppl 1):S1-5. PubMed ID: 17941451
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of DRD1 and DRD3 Polymorphisms in the Occurrence of Motor Effects in Patients with Sporadic Parkinson's Disease.
    Dos Santos EUD; Duarte EBC; Miranda LMR; Asano AGC; Asano NMJ; Maia MMD; de Souza PRE
    Neuromolecular Med; 2019 Sep; 21(3):295-302. PubMed ID: 31119645
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.